Australia markets closed

Vitura Health Limited (VIT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1600-0.0100 (-5.88%)
At close: 03:45PM AEST
Full screen
Previous close0.1700
Open0.1700
Bid0.1600 x N/A
Ask0.1700 x N/A
Day's range0.1600 - 0.1700
52-week range0.1300 - 0.6000
Volume35,346
Avg. volume263,525
Market cap92.14M
Beta (5Y monthly)0.16
PE ratio (TTM)8.00
EPS (TTM)0.0200
Earnings date27 Feb 2024
Forward dividend & yield0.01 (5.88%)
Ex-dividend date04 Sept 2023
1y target estN/A
  • GlobeNewswire

    Cronos Enters Australian Cannabis Market

    TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited (“Vitura”) (ASX: VIT). Cronos owns approximately 10% of the common shares of Vitura, formerly known as Cronos Australia, and will supply cannabis for Vitura. “Supplying the Australian market, which has grown significantly in the past three

  • GlobeNewswire

    PharmAla Files Audited Financials for Year Ending August 31, 2023

    Highlights include Revenue Growth, Expansion of IP Licensing, and formation of Cortexa Joint VentureVANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to file its audited financial statements for the year ended on August 31, 2023. Following is a short list of th

  • GlobeNewswire

    PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

    Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian